Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 5th Annual NASH Summit from November 29 to December 2, 2021. Dr. Fishman's presentation, scheduled for December 1 at 1:30 PM ET, will discuss the Phase 2a study of Namodenoson, an A3AR Agonist, in treating Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. The 5th Annual NASH Summit gathers experts to enhance understanding of NASH clinical science. Namodenoson recently completed a successful Phase IIa trial, meeting its primary endpoint.
Can-Fite BioPharma announced that its veterinary partner, Vetbiolix, has initiated a safety and efficacy study of Piclidenoson for treating canine osteoarthritis, targeting a market expected to reach $3 billion by 2024. Safety results are anticipated in Q1 2022, with efficacy data expected in Q4 2022. Piclidenoson has shown a favorable safety profile in over 1,500 human patients. The study aims to provide a safer alternative to existing treatments, with Vetbiolix responsible for development costs and potential royalties upon regulatory approval.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, at 12:30 PM ET. The presentation will emphasize Can-Fite's advanced-stage pipeline, including a Phase III study in psoriasis with results expected in Q1 2022. Upcoming studies include a Phase II study in NASH and a pivotal Phase III trial in liver cancer. Can-Fite is focused on developing proprietary drugs for inflammatory diseases, cancer, and liver conditions, including the candidates Piclidenoson and Namodenoson.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present research on the CBD Rich T3/C15 cannabis fraction at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting from November 12-15, 2021. The study indicates that this cannabis fraction inhibits the growth of HEP-3b hepatocellular carcinoma cells via the A3 Adenosine Receptor. This inhibitory activity suggests potential therapeutic applications in liver cancer treatment.
Can-Fite BioPharma (NYSE: CANF) announced the granting of a patent for its NASH drug candidate, Namodenoson, in Hong Kong and Mexico, with a notice of allowance in Japan. This patent enhances Can-Fite's intellectual property in treating ectopic fat accumulation related to NAFLD and NASH, projected to reach a $35 billion market by 2025. Namodenoson has successfully completed a Phase IIa study and is currently in Phase IIb trials. The company has secured about $20 million in non-dilutive payments for Namodenoson across multiple regions.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 5th Annual Antifibrotic Drug Development Summit on November 3, 2021. Her presentation will highlight innovative strategies for promoting tissue regeneration, focusing on clinical trial data for Namodenoson, which showed a dose-dependent reduction in liver fat and fibrosis in a Phase IIa study. The Phase IIb study is currently approved and underway, while Can-Fite continues to advance its clinical pipeline in cancer and liver diseases.
Can-Fite BioPharma Ltd (NYSE: CANF) announced the publication of a study on Namodenoson for treating non-alcoholic fatty liver disease (NASH) in the journal Alimentary Pharmacology & Therapeutics. The Phase IIa trial met its endpoints, showcasing significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects. A Phase IIb trial is set to enroll patients in Q4 2021. The market for NASH treatments is projected to reach $35-40 billion by 2025. With no current U.S. approved drugs for NASH, the potential for Namodenoson is substantial.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the NASH Investor Conference on October 12, 2021, at 9:30 am ET. The conference will include a panel of experts discussing NASH, a liver disease with no approved treatments in the U.S. Can-Fite's drug candidate, Namodenoson, is set to enter a Phase IIb trial for NASH in Q4 2021, following successful Phase IIa results. The NASH market is projected to reach $35-40 billion by 2025.
Can-Fite BioPharma Ltd. (NYSE American: CANF) will have CEO Dr. Pnina Fishman present at the Benzinga Healthcare Small Cap Conference on September 29, 2021.
The presentation will include a panel discussion on medical cannabis and insights into Can-Fite’s drug development efforts, including ongoing trials for Piclidenoson and Namodenoson targeting psoriasis and liver cancer. With FDA designations for Namodenoson, Can-Fite aims to capture significant market opportunities in the pharmaceutical industry.
Can-Fite BioPharma Ltd (NYSE American: CANF) has secured approximately $20 million from partnering deals, with potential for an additional $130 million in milestone payments and royalties. The company will participate in three upcoming virtual conferences to meet with potential partners for its drug candidates targeting cancer, liver diseases, and inflammation. Key events include BioPharm America 2021 (Sept 20-23), TAP Diabetes 2021 (Oct 5-7), and BIO-Europe 2021 (Oct 25-29). Can-Fite's leading candidates are in advanced clinical stages.